Artelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SOLANA BEACH, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.

Gregory Gorgas, CEO of Artelo Biosciences, is scheduled to present on September 13, 2023 at 2:00 PM Eastern Time. The presentation will be webcast live on the conference event platform, which can be accessed at https://journey.ct.events/view/a3fb36ce-8e0f-41c1-b530-feebded86361 and on the investor relations section of Artelo’s website at https://ir.artelobio.com/.

Management will be participating in one-on-one meetings with qualified members of the investor community throughout the conference in New York City. To request a meeting, please contact ARTL@crescendo-ir.com

About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways including the endocannabinoid system. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, neuropathy, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.

Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com

Staff

Recent Posts

MedsEngine Achieves High Blood Pressure Control In Less Than Two Office Visits

DAYTON, Ohio--(BUSINESS WIRE)--MedsEngine LLC, a provider of chronic disease management software, presented its findings on…

16 minutes ago

Clarivate and CAPES Expand Landmark Partnership to Power Research and Innovation Across Brazil

New five-year agreement delivers critical academic and life sciences insights into more than 400 institutions,…

19 minutes ago

Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub

Montreal, Quebec--(Newsfile Corp. - June 2, 2025) -  Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE:…

2 hours ago

TMCI Deadline: Rosen Law Firm Urges Treace Medical Concepts, Inc. (NASDAQ: TMCI) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a…

18 hours ago

Introducing Tempus One in the EHR with Integrated Guidelines

The AI-enabled clinical assistant is available to query patient data across the EHR as well…

21 hours ago

Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis

33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer (EBC)…

21 hours ago